Near full genome characterization of HIV-1 unique recombinant forms in Cameroon reveals dominant CRF02_AG and F2 recombination patterns.
Env epitopes and drug resistance mutations
intra-patient viral diversity
near full genome sequencing
third-generation sequencing
unique recombinant forms
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
19
12
2018
accepted:
04
07
2019
entrez:
30
7
2019
pubmed:
30
7
2019
medline:
28
4
2020
Statut:
ppublish
Résumé
In Cameroon, a manifold diversity of HIV strains exists with CRF02_AG and unique recombinant forms (URFs) being the predominant strains. In recent years, a steady increase in URFs and clade F2 viruses has been monitored through partial genome sequencing. There is an information gap in the characterization of emerging URFs along the full genome, which is needed to address the challenges URFs pose towards diagnosis, treatment and HIV-1 vaccine design. Eighteen Cameroonian URFs from samples collected between the years 2000 and 2015 were studied using a newly developed near full genome sequencing (NFGS) protocol based on variable nested RT-PCRs with a versatile primer set. Near full genomes were characterized for recombination patterns and sequence signatures with possible impact on antiretroviral treatment or Env-directed immune responses. Third-generation sequencing (3GS) of near full or half genomes (HGs) gave insight into intra-patient URF diversity. The characterized URFs were composed of a broad variety of subtypes and recombinants including A, F, G, CRF01_AE, CRF02_AG and CRF22_01A1. Phylogenetic analysis unveiled dominant CRF02_AG and F2 recombination patterns. 3GS indicated a high intra-patient URF diversity with up to four distinct viral sub-populations present in plasma at the same time. URF pol genomic analysis revealed a number of accessory drug resistance mutations (DRMs) in the ART-naïve participants. Genotypic env analysis suggests CCR5 usage in 14/18 samples and identified deviations at residues, critical for gp120/gp41 interphase and CD4 binding site broadly neutralizing antibodies in more than half of the studied URFs. V1V2 sites of immune pressure in the human RV144 vaccine study varied in more than a third of URFs. This study identified novel mosaic patterns in URFs in Cameroon. In line with the regional predominance of CRF_02AG and the increased prevalence of clade F2, prominent CRF_02AG and F2 background patterns were observed underlying the URFs. In the context of the novel mosaic genomes, the impact of the identified accessory DRMs and Env epitope variations on treatment and immune control remains elusive. The evolving diversity of HIV-1 URFs in Cameroon requires continuous monitoring to respond to the increasing challenges for diagnosis, antiretroviral treatment and prevention.
Identifiants
pubmed: 31353798
doi: 10.1002/jia2.25362
pmc: PMC6661401
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25362Subventions
Organisme : Welcome Trust
ID : 107
Pays : International
Organisme : Welcome Trust
ID : 752/Z/15/Z
Pays : International
Informations de copyright
© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
J Infect. 2013 May;66(5):391-400
pubmed: 23103289
Bioinformatics. 2014 May 1;30(9):1312-3
pubmed: 24451623
Nature. 2012 Oct 18;490(7420):417-20
pubmed: 22960785
J Med Virol. 2010 Feb;82(2):187-96
pubmed: 20029816
Virus Evol. 2018 Jun 11;4(1):vey015
pubmed: 29942655
J Med Virol. 2014 Mar;86(3):385-93
pubmed: 24248638
Viruses. 2010 Feb 12;2(2):639-654
pubmed: 21072143
J Virol. 1998 May;72(5):3534-8
pubmed: 9557632
Virology. 2003 Jun 5;310(2):254-66
pubmed: 12781713
J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):432-9
pubmed: 18931623
AIDS Res Hum Retroviruses. 2007 Aug;23(8):1008-19
pubmed: 17725418
Lancet Infect Dis. 2019 Feb;19(2):143-155
pubmed: 30509777
Evol Appl. 2014 Nov;7(9):1026-42
pubmed: 25553065
Retrovirology. 2010 Apr 28;7:39
pubmed: 20426823
AIDS Res Hum Retroviruses. 2016 Apr;32(4):381-5
pubmed: 26681241
J Virol. 2014 Mar;88(5):2891-902
pubmed: 24371048
J Virol. 2005 Jul;79(14):9026-37
pubmed: 15994796
Evol Med Public Health. 2015 Sep 09;2015(1):254-65
pubmed: 26354000
AIDS Res Hum Retroviruses. 2007 Jul;23(7):923-33
pubmed: 17678477
AIDS. 1994 Oct;8(10):1405-12
pubmed: 7818811
Immunity. 2014 May 15;40(5):657-68
pubmed: 24768347
Gigascience. 2017 Mar 1;6(3):1-10
pubmed: 28327976
J Acquir Immune Defic Syndr. 2006 Sep;43(1):15-22
pubmed: 16885781
Virol J. 2013 Jan 22;10:29
pubmed: 23339631
Clin Infect Dis. 2019 Jan 7;68(2):177-187
pubmed: 30052811
J Virol. 2002 Nov;76(21):10745-55
pubmed: 12368317
Expert Rev Anti Infect Ther. 2013 Nov;11(11):1159-78
pubmed: 24151833
Infect Genet Evol. 2007 Dec;7(6):717-23
pubmed: 17851137
PLoS One. 2009;4(3):e4724
pubmed: 19266092
New Microbiol. 2009 Oct;32(4):325-31
pubmed: 20128438
J Virol. 2003 Dec;77(23):12921-6
pubmed: 14610215
PLoS Comput Biol. 2008 Sep 12;4(9):e1000178
pubmed: 18787691
Top Antivir Med. 2017 Dec/Jan;24(4):132-133
pubmed: 28208121
J Clin Virol. 2016 Mar;76:51-4
pubmed: 26826578
PLoS One. 2017 Mar 13;12(3):e0173705
pubmed: 28288209
J Clin Microbiol. 2008 Jan;46(1):177-84
pubmed: 17855574
J Virol. 2017 Feb 28;91(6):
pubmed: 28077647
AIDS Res Hum Retroviruses. 2006 Aug;22(8):812-6
pubmed: 16910839
Mol Biol Evol. 2011 Oct;28(10):2731-9
pubmed: 21546353
Antivir Ther. 2009;14(3):401-11
pubmed: 19474474
J Virol. 2015 Dec 09;90(5):2221-9
pubmed: 26656688
Science. 2006 Jul 28;313(5786):523-6
pubmed: 16728595
Curr HIV Res. 2007 Jan;5(1):23-45
pubmed: 17266555
Expert Rev Anti Infect Ther. 2013 Sep;11(9):885-96
pubmed: 24011334
AIDS. 2011 Mar 13;25(5):679-89
pubmed: 21297424
J Int AIDS Soc. 2019 Jul;22(7):e25362
pubmed: 31353798
N Engl J Med. 2009 Dec 3;361(23):2209-20
pubmed: 19843557
Lancet Infect Dis. 2013 Jul;13(7):622-8
pubmed: 23726798
Science. 2011 Sep 16;333(6049):1633-7
pubmed: 21764753
Bioinformatics. 2010 Jun 15;26(12):i132-9
pubmed: 20529898
Virol J. 2011 Apr 23;8:185
pubmed: 21513545
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006841
pubmed: 22229120
Science. 2014 Oct 3;346(6205):56-61
pubmed: 25278604
Sci Rep. 2015 Feb 25;5:8543
pubmed: 25712827
J Virol. 2014 Mar;88(5):2489-507
pubmed: 24352443
J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):495-505
pubmed: 12473838
Nat Biotechnol. 2018 Apr;36(4):338-345
pubmed: 29431738
J Acquir Immune Defic Syndr. 2006 Jul;42(3):331-41
pubmed: 16639350
AIDS. 2008 Mar 12;22(5):611-6
pubmed: 18317002
Sci Rep. 2016 Aug 30;6:31900
pubmed: 27573208
PLoS One. 2017 May 8;12(5):e0177281
pubmed: 28481902
Lancet Infect Dis. 2011 Jan;11(1):45-56
pubmed: 21126914
Viruses. 2019 Apr 01;11(4):
pubmed: 30939815
J Med Virol. 2012 May;84(5):721-7
pubmed: 22431019
J Clin Microbiol. 2017 Sep;55(9):2785-2800
pubmed: 28659324
J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):344-50
pubmed: 22549382
J Virol Methods. 2010 Sep;168(1-2):114-20
pubmed: 20451557
J Virol Methods. 2016 Oct;236:98-104
pubmed: 27448822
J Clin Microbiol. 2002 Mar;40(3):837-45
pubmed: 11880402